This page is intended to provide scientific information to scientific research professionals. Gossamer Bio’s drug candidates are investigational medicines and have not been approved by The United States Food and Drug Administration (USFDA), Health Canada, the European Medicines Agency (EMA), nor any other regulatory agency.

Publications

Pharmacology and Rationale for Seralutinib in the Treatment of Pulmonary Arterial Hypertension

International Journal of Molecular Sciences – August 2023

Inhaled Seralutinib Exhibits Potent Efficacy in Models of Pulmonary Arterial Hypertension

European Respiratory Journal – June 2022

TORREY, a Phase 2 Study to Evaluate the Efficacy and Safety of Inhaled Seralutinib for the Treatment of Pulmonary Arterial Hypertension

Pulmonary Circulation – October 2021

Scientific Congresses

Sustained effect of seralutinib on circulating biomarkers: Lessons from the TORREY phase 2 open-label extension study

ERS – September 2024

Sustained benefit with seralutinib treatment: a post-hoc analysis of the TORREY open-label extension

ERS – September 2024

Reverse remodeling and anti-proliferative effects of seralutinib in PAH precision-cut lung slices and pulmonary artery smooth muscle cells

ERS – September 2024

See More

Seralutinib MOA Video

A targeted approach to the proliferation, fibrosis, and inflammation associated with Pulmonary Arterial Hypertension

Targeting the underlying mechanisms of Pulmonary Arterial Hypertension

We are a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension. Our goal is to enhance the lives of people living with pulmonary hypertension.

program
discovery
phase 1
phase 2
phase 3
+

Seralutinib (GB002) –
Pulmonary Arterial Hypertension

Inhaled PDGFR, CSF1R, c-KIT inhibitor
Phase 3 PROSERA Study now enrolling worldwide

clinical trials

GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)

Condition: Pulmonary Arterial Hypertension
Phase: Phase 3 PROSERA Study now enrolling worldwide
Description: The primary objective for this trial is to determine the effect of GB002 on improving pulmonary hemodynamics in subjects with World Health Organization (WHO) Group 1 PAH who are Functional Class (FC) II and III. The secondary objective for this trial is to determine the effect of GB002 on improving exercise capacity in this population.

View on ClinicalTrials.gov
collapse window

recent posters and publications

Sustained effect of seralutinib on circulating biomarkers: Lessons from the TORREY phase 2 open-label extension study

ERS – September 2024

Sustained benefit with seralutinib treatment: a post-hoc analysis of the TORREY open-label extension

ERS – September 2024

view more publications